Mission:
 To discover and develop better, faster-acting, and more affordable drugs to fight tuberculosis.

Background:
 The TB Alliance was conceived in February 2000 in Cape Town, South Africa, by a group of scholars, NGO representatives, and other stakeholders who had gathered to discuss the need for new treatments. The discussion led to the creation of the Declaration of Cape Town, which provided a guide to TB drug development and an outline for the creation of the alliance, which was formally launched a few months later. Headquartered in New York City, with offices in Brussels and Pretoria, the TB Alliance is a product development partnership (PDP) that works to drive the development of new products for diseases of poverty. The organization and its public, private, academic, and philanthropic partners currently manage a robust portfolio of new TB drug candidates.

Outstanding Web Features:
 The recently redesigned TB Alliance Web site features a Voices of TB portal that includes video perspectives from those affected by the disease; a section on regimen development, an innovative clinical development paradigm that can speed the development of novel drug combinations; and information on challenges associated with the TB epidemic, including inadequate treatments, HIV-TB co-infection, multi-drug and extremely-drug-resistant TB, and the economic impact of the disease. The site also offers related resources, a list of publications, and a keyword-searchable news center.